Using Esterase Selectivity to Determine the <i>In Vivo</i> Duration of Systemic Availability and Abolish Systemic Side Effects of Topical β-Blockers
Jillian G. Baker(Nottingham University Hospitals NHS Trust), Peter M. Fischer(University of Nottingham), Barrie Kellam(University of Nottingham), Marjorie Bruder(West Midlands Deanery), Stephen J. Hill(University of Nottingham), Kevin S. J. Thompson(University of Nottingham), Sheila M. Gardiner(University of Nottingham), Christophe Fromont(University of Nottingham)
Cited by 4
Related Papers
Structure of a β1-adrenergic G-protein-coupled receptor
|Nature|2008|1.3k
The structural basis for agonist and partial agonist action on a β1-adrenergic receptor
|Nature|2011|623
The selectivity of β‐adrenoceptor agonists at human β<sub>1</sub>‐, β<sub>2</sub>‐ and β<sub>3</sub>‐adrenoceptors
|British Journal of Pharmacology|2010|586
The selectivity of <i>β</i>‐adrenoceptor antagonists at the human <i>β</i>1, <i>β</i>2 and <i>β</i>3 adrenoceptors
|British Journal of Pharmacology|2005|535
The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors
|British Journal of Pharmacology|2023|390